Busy dealing-making days for BridgeBio
BridgeBio Pharma - Innovation Showcase at Ophthalmology Innovation Summit @ AAO 2019 - YouTube
BridgeBio keeps FDA approval spree rolling, this time with nod for targeted bile duct cancer med | Fierce Pharma
S-1
Bridgebio files lung cancer drug trial plans in US, Korea
Is BridgeBio Pharma Stock a Buy on the Dip? | The Motley Fool
Bridgebio Pharma - Selling Group Member June 2019 - A Service Disabled Veteran Broker Dealer
BridgeBio | Biotechnology Company | Designing Transformative Medicines
BridgeBio turns Alexion asset into first approved drug for rare metabolic disease - MedCity News
Neil Kumar - founder and CEO of BridgeBio, superforecaster in rare disease drug development - YouTube
BridgeBio Pharma Licenses Late-Stage Oncology Drug Infigratinib to Tackle FGFR-Driven Maladies; Establishes New Subsidiary QED Therapeutics with $65 Million in Initial Financing
BridgeBio Pharma, Inc. Reports Second Quarter 2022 Financial Results and Business Update
BridgeBio | LinkedIn
S-1
BridgeBio Pharma on Twitter: "We are thrilled to have received our first international approval for our first cancer therapy – paving the way for patients in Canada to receive our medicine targeting
Hub-and-spoke' biotech BridgeBio scores first FDA approval with Alexion castoff | Fierce Pharma
BridgeBio | LinkedIn
BridgeBio Pharma Reports Third Quarter 2021 Financial Results and Business Update
BridgeBio | Biotechnology Company | Designing Transformative Medicines
After layoffs, BridgeBio seeks partners for 6 drug candidates
Bullish on Breakthroughs
BridgeBio CSO departs amid company's second round of layoffs
